No Data
No Data
CNS Pharmaceuticals Regains Compliance With Nasdaq Equity Requirement
CNS Pharma Analyst Ratings
Maxim Group Upgrades CNS Pharmaceuticals(CNSP.US) to Buy Rating, Announces Target Price $0.5
Express News | CNS Pharmaceuticals Inc : Maxim Group Raises to Buy From Hold
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Express News | Ibn Announces Latest Episode of the Biomedwire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
No Data
No Data